Swiftly Meds Private Limited

ChatGPT said:

Lenvima 4 mg Tablets contain lenvatinib, a medication used to treat certain types of cancer, including thyroid cancer, liver cancer, and renal cell carcinoma (kidney cancer). It works by inhibiting multiple tyrosine kinases, which are involved in cancer cell growth and blood vessel formation. Lenvima helps slow the progression of cancer by targeting these pathways and is typically prescribed for patients who have not responded to other treatments.

 

Canmab 440 mg Injection

Generic Name: Trastuzumab
Brand Name: Canmab
Strength: 440 mg
Dosage Form: Injection

Indications: Canmab (trastuzumab) is a monoclonal antibody used in the treatment of HER2-positive cancers. It is commonly prescribed for patients with the following conditions:

• Breast Cancer (HER2-positive): Used in the adjuvant treatment of HER2-positive breast cancer, including both early-stage and metastatic forms. It is also used for patients who have not previously received chemotherapy for metastatic breast cancer.

• Gastric Cancer (HER2-positive): Canmab is used to treat HER2-positive gastric cancer in combination with chemotherapy in patients with advanced or metastatic disease.

• Adjuvant Therapy: In combination with chemotherapy, it is indicated for the treatment of HER2-positive breast cancer post-surgery to reduce the risk of cancer recurrence.

Mechanism of Action: Canmab contains trastuzumab, a humanized monoclonal antibody that specifically targets the HER2 receptor, a protein present in excess on the surface of some cancer cells. Trastuzumab binds to this receptor, preventing the proliferation of cancer cells. Additionally, it can stimulate immune system activity, which leads to the destruction of HER2-positive cells.

Dosage and Administration:

• Initial Dose: For breast cancer, the initial dose is typically 8 mg/kg body weight, administered as an intravenous infusion.

• Subsequent Doses: After the initial dose, Canmab is usually given as 6 mg/kg every three weeks as a maintenance dose.

• Gastric Cancer: The dosing regimen for gastric cancer involves similar dosing as for breast cancer.

• Canmab should be administered under the supervision of a healthcare professional experienced in cancer therapy.

Important Precautions:

• Cardiac Toxicity: Canmab has been associated with heart-related side effects such as left ventricular dysfunction, heart failure, and reduced ejection fraction. Cardiac function should be monitored before, during, and after treatment.

• Infusion Reactions: Serious infusion reactions, including chills, fever, nausea, vomiting, and hypotension, can occur during administration. The infusion rate should be adjusted or the therapy paused if severe reactions occur.

• Pregnancy Category: Canmab is classified as a Category D drug in pregnancy, meaning it may harm an unborn baby. Women should avoid pregnancy during treatment.

• Lung Toxicity: Interstitial lung disease and pneumonitis have been observed, and patients should be monitored for respiratory symptoms.

Side Effects: Common side effects of Canmab include fever, fatigue, nausea, headache, diarrhea, and loss of appetite. Serious side effects can include:

• Heart problems (including heart failure)

• Infusion reactions

• Lung problems (such as breathing difficulties)

• Low blood cell counts, which can lead to increased risk of infections, anemia, or bleeding

Storage: Store Canmab in a refrigerator (2°C to 8°C). It should not be frozen. The vial should be protected from light, and the solution should not be used if it appears cloudy or contains particles.

Denosumab Solution for Injection 120 mg is a medication primarily used to treat conditions associated with bone loss, such as osteoporosis and certain types of bone metastases. The active ingredient, Denosumab, is a fully human monoclonal antibody that targets and inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). RANKL plays a key role in the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. By inhibiting RANKL, Denosumab reduces the activity of osteoclasts, leading to a decrease in bone resorption, an increase in bone density, and a reduction in the risk of fractures.

This injectable medication is administered subcutaneously (under the skin) and is typically used in adults who have conditions such as:

1. Osteoporosis: Denosumab is used to increase bone mass and strength in individuals with osteoporosis, particularly those at high risk of fractures. It is recommended for postmenopausal women and men with osteoporosis who are at high risk of fractures.

2. Bone loss due to cancer treatments: It is also used in patients with bone loss related to cancer therapies like aromatase inhibitors or androgen deprivation therapy.

3. Bone metastases from cancer: Denosumab is prescribed for patients with bone metastases from solid tumors to prevent skeletal-related events like fractures, spinal cord compression, or the need for radiation or surgery to bone.

4. Other bone conditions: In some cases, it may be used for patients with other conditions leading to bone resorption, including giant cell tumor of bone.

The 120 mg dose is typically administered every 4 weeks for specific indications, and the treatment can be given by a healthcare provider. It is important to note that patients undergoing treatment with Denosumab may require supplementation with calcium and vitamin D to prevent complications related to low calcium levels, as the drug's effect on bone resorption can result in changes in calcium metabolism.

As with all medications, there are potential side effects associated with Denosumab, including infections, bone pain, musculoskeletal pain, and potential fractures upon discontinuation. Rare, but serious, side effects include osteonecrosis of the jaw and atypical femur fractures.

Patients should discuss any pre-existing medical conditions and medications they are currently taking with their healthcare provider before starting Denosumab. Regular monitoring of bone health, calcium levels, and renal function is essential during treatment.

Emetant 125/80 mg capsules contain Ferrous Ascorbate (125 mg) and Folic Acid (80 mg). They are commonly used to treat or prevent iron and folate deficiencies, such as in cases of anemia. The combination supports red blood cell production and helps in maintaining overall health during pregnancy or in individuals with low iron levels.

The Fixpritant Kit is typically used to manage nausea and vomiting, often associated with chemotherapy treatments. It contains Palonosetron (an antiemetic) and Dexamethasone (a corticosteroid) to prevent these symptoms. Palonosetron works by blocking serotonin receptors that trigger nausea, while Dexamethasone helps reduce inflammation and enhances the effectiveness of anti-nausea treatments. The kit is used under medical supervision to ensure the proper dosage and effectiveness.

Nelova (Nilotinib) 150 mg Capsules

Description: Nelova is a brand name for nilotinib, a targeted therapy used primarily for the treatment of chronic myelogenous leukemia (CML), specifically in patients who are Philadelphia chromosome-positive (Ph+), which means their leukemia cells have a specific genetic abnormality. Nilotinib is a tyrosine kinase inhibitor (TKI) that works by blocking the action of an enzyme called BCR-ABL tyrosine kinase, which is produced by the Philadelphia chromosome. This abnormal enzyme promotes the growth of cancer cells in leukemia. By inhibiting this enzyme, nilotinib can slow down or stop the growth of leukemia cells.

 

Uses of Nelova (Nilotinib) 150 mg Capsules:

1. Chronic Myelogenous Leukemia (CML): Nelova is primarily used in the treatment of CML in patients who are positive for the Philadelphia chromosome (Ph+). It is indicated for both the chronic phase and accelerated phase of CML, especially in cases where the disease is resistant or intolerant to other treatments like imatinib.

2. First-Line Treatment: In some cases, Nelova may be used as a first-line treatment for newly diagnosed CML in the chronic phase.

3. Imatinib-Resistant or Imatinib-Intolerant CML: Nelova is also prescribed for patients who have either resistant or intolerant CML after having been treated with imatinib.

4. Other Types of Leukemia: While Nelova is most commonly used for CML, research and clinical trials have shown that nilotinib may have potential use in other hematologic malignancies, though its primary indication is CML.

Side Effects of Nelova (Nilotinib) 150 mg Capsules:

As with any medication, Nelova (nilotinib) can cause side effects, some of which can be serious. The side effects may range from mild to severe and should be closely monitored by healthcare providers. Common side effects include:

1. Common Side Effects:

   • Fatigue: Patients often report feeling tired or fatigued during treatment.

   • Headache: Headaches are a common side effect experienced by patients.

   • Nausea and Vomiting: Gastrointestinal discomfort such as nausea and vomiting is relatively common.

   • Rash: Some patients develop a rash during treatment.

   • Muscle or Joint Pain: Nilotinib may cause mild muscle or joint aches and pains.

   • Diarrhea or Constipation: Some gastrointestinal disturbances, such as diarrhea or constipation, can occur.

2. Storage Conditions for Nelova (Nilotinib) 150 mg Capsules:

1. Temperature: Nelova capsules should be stored at room temperature, typically between 20°C to 25°C (68°F to 77°F). They should be kept in a cool, dry place, away from excessive heat or moisture.

2. Out of Reach of Children: As with all medications, Nelova should be kept out of reach of children to prevent accidental ingestion.

Afinitor 10 mg Tablet (Everolimus) – Targeted Treatment for Cancer and Other Conditions

What is Afinitor 10 mg Tablet? Afinitor 10 mg Tablet contains Everolimus, an oral medication that acts as a mTOR inhibitor, used in the treatment of certain types of cancer and non-cancerous conditions. Everolimus works by blocking the mTOR protein, which plays a key role in cell growth, metabolism, and survival, thereby slowing down or stopping the growth of cancer cells

How Does Afinitor Work? Everolimus inhibits the mTOR (mechanistic target of rapamycin) pathway, which is involved in regulating cell growth and division. By blocking this pathway, Afinitor helps to prevent the proliferation of cancer cells and tumor growth in various cancers, as well as non-cancerous tumors. It’s effective in treating cancers that are resistant to conventional treatments, as well as certain benign tumors
Indications: Afinitor 10 mg Tablet is prescribed for

• Advanced kidney cancer (Renal Cell Carcinoma - RCC)For patients whose disease has progressed despite other treatments.
• Breast cancer: In combination with other therapies for hormone receptor-positive breast cancer.
• Neuroendocrine tumors: Including those in the pancreas and gastrointestinal system.
• Tuberous Sclerosis Complex (TSC): For the treatment of non-cancerous tumors (e.g., renal angiomyolipoma and subependymal giant cell astrocytomas).
• Advanced non-small cell lung cancer (NSCLC): In combination with other chemotherapy agents.
  Dosage and Administration: The typical dosage for Afinitor 10 mg Tablet is 10 mg once daily, taken with or without food. The tablet should be swallowed whole, not crushed or chewed. Dosage may be adjusted depending on the patient's condition, response to treatment, and side effects. Regular monitoring and follow-up visits are essential during treatment to adjust the dosage if necessary.

Benefits of Afinitor:

• Targeted therapy: Specifically blocks the mTOR pathway, directly inhibiting tumor growth.
• Multiple indications: Effective for various cancers and benign tumors.
• Convenient oral administration: Taken once daily, ensuring ease of use for patients.
• Proven efficacy: Clinical studies have demonstrated the effectiveness of Everolimus in advanced cancers and non-cancerous tumor conditions.
  
  Side Effects: Common side effects include:

• Mouth sores (stomatitis)
• Fatigue
• Rash
• Loss of appetite
• Diarrhea

Serious side effects may include:

• Lung problems: Such as shortness of breath or cough.
• Infections: Due to immune system suppression.
• Liver problems: Regular liver function tests are recommended.
• High blood sugar or diabetes.
  If any severe side effects occur, contact your healthcare provider immediately.

Precautions: Before using Afinitor 10 mg Tablet, inform your doctor if you have:

• Liver or kidney problems
• Infections or a history of lung disease
• Diabetes or elevated blood sugar
• Any allergies to Everolimus or other components of the tablet
• Are pregnant or breastfeeding, as Everolimus can harm the fetus or infant.

Drug Interactions: Afinitor may interact with other medications, including antifungals, antibiotics, antivirals, and HIV medications. Always inform your doctor about any other drugs you are taking

Pegreligrast 6 mg Injection is a medication used to reduce the risk of infection in patients receiving chemotherapy. It is a granulocyte colony-stimulating factor (G-CSF) that helps stimulate the bone marrow to produce more white blood cells, particularly neutrophils, which are essential for fighting infections.

Generic Name:

• Pegfilgrastim (Pegreligrast is the brand name)

Uses:

• Chemotherapy-induced Neutropenia: Pegreligrast is primarily used to reduce the risk of infection due to low white blood cell counts in patients undergoing chemotherapy for cancer.
• Other Uses: It may also be used in certain conditions where a patient has a low neutrophil count, such as severe chronic neutropenia.

Benefits:

• Prevents Infections: Pegreligrast increases white blood cell production, which lowers the chance of serious infections.
• Improves Chemotherapy Tolerance: By reducing neutropenia (low neutrophil count), it helps patients tolerate chemotherapy better and avoid treatment delays.
• Reduces the Need for Hospitalization: Pegreligrast may decrease the need for hospitalization due to infection by boosting immune defense.

Dosage and How to Take:

• Standard Dose: The usual dose is 6 mg once per chemotherapy cycle, administered as a single subcutaneous injection.
• Administration: The injection is given under the skin (subcutaneously), typically by a healthcare provider.
• Frequency: It is usually administered 24 hours after the last chemotherapy dose and given once per cycle. The dose schedule may vary based on the individual patient's condition.

Storage:

• Conditions: Store the medication in a refrigerator at 2°C to 8°C (36°F to 46°F).
• Do Not Freeze: Do not freeze the injection. If frozen, it should not be used.
• Keep out of reach of children and protect from light.

Side Effects:

Common side effects include:

• Bone Pain: Pain in bones or muscles is a frequent side effect.
• Injection Site Reactions: Redness, pain, or swelling at the injection site.
• Fever: Some patients experience mild fever after the injection.
• Headache or Fatigue: Feeling tired or having a headache may occur.
• Splenic Rupture (rare): Though rare, Pegreligrast has been associated with an increased risk of spleen problems, including rupture. Seek immediate medical attention if you experience pain in the left upper abdomen or shoulder.
• Allergic Reactions: Severe allergic reactions, such as rash, difficulty breathing, or swelling, are rare but possible.

Precautions:

• Pre-existing Conditions: Inform your healthcare provider if you have a history of spleen problems, lung disease, or other serious medical conditions.
• Pregnancy and Breastfeeding: Pegreligrast should only be used during pregnancy if clearly needed, and breastfeeding while on the medication is not recommended.
• Monitor for Side Effects: Your doctor may monitor your blood counts and kidney or liver function while you're on treatment.

Drug Interactions:

• Chemotherapy Drugs: Pegreligrast is often used in combination with chemotherapy, so interactions are minimal. However, your doctor will monitor for any unusual effects when used alongside chemotherapy agents.
• Other Medications: Always inform your doctor of all medications you're taking, including over-the-counter drugs, to avoid any potential interactions.

Advamab 100mg Injection: Overview, Uses, and Side Effects

Advamab 100mg Injection contains Bevacizumab, a monoclonal antibody used primarily in the treatment of various cancers. It works by inhibiting vascular endothelial growth factor (VEGF), a protein responsible for promoting the growth of blood vessels. By blocking VEGF, Advamab reduces the blood supply to tumors, effectively slowing or halting their growth and spread.

Key Information:

• Generic Name: Bevacizumab
• Brand Name: Advamab
• Strength: 100mg per vial
• Form: Injectable solution for intravenous use
• Manufacturer: Varies (depending on region)

Indications:

Advamab 100mg Injection is commonly prescribed for:

1. Metastatic Colorectal Cancer (mCRC): Often used in combination with chemotherapy for advanced colon cancer.
2. Non-Small Cell Lung Cancer (NSCLC): Administered with chemotherapy to treat advanced-stage lung cancer.
3. Renal Cell Carcinoma (RCC): Used for metastatic kidney cancer.
4. Glioblastoma Multiforme (GBM): For recurrent brain cancer.
5. Ovarian Cancer: For advanced ovarian cancer, typically in combination with other chemotherapy agents.
6. Cervical Cancer: For recurrent or metastatic cervical cancer in combination with chemotherapy.

How It Works:

Advamab contains Bevacizumab, which binds to VEGF, preventing it from stimulating the growth of new blood vessels (angiogenesis). Tumors rely on these blood vessels for nutrients and oxygen. By inhibiting VEGF, Advamab reduces blood supply to tumors, thus slowing or stopping their growth.

Dosage and Administration:

Advamab 100mg Injection is given intravenously by a healthcare provider. The dosage varies based on the type of cancer being treated and the patient's response. Common dosing regimens include:

• Colorectal Cancer: 5 mg/kg every two weeks in combination with chemotherapy.
• Lung Cancer: 15 mg/kg every three weeks with chemotherapy.
• The exact dose may be adjusted depending on individual circumstances and specific treatment protocols.

Side Effects:

While Advamab is effective in treating various cancers, it may cause side effects, including:

• Common side effects: Fatigue, nausea, diarrhea, high blood pressure, and protein in urine.
• Serious side effects: Risk of bleeding, blood clots, gastrointestinal perforation, and heart problems.
• Other effects: Allergic reactions such as rash, swelling, and difficulty breathing.

It is essential for patients to be monitored closely during treatment, especially for blood pressure and bleeding issues.

Precautions:

1. Pregnancy and Breastfeeding: Not recommended for use during pregnancy or breastfeeding due to potential harm to the baby.
2. Pre-existing conditions: Inform your doctor if you have heart disease, high blood pressure, or a history of bleeding or clotting disorders.
3. Drug interactions: Advamab may interact with other medications, especially those affecting blood clotting. Always inform your healthcare provider about all medications you're currently taking.

Conclusion:

Advamab 100mg Injection is a powerful treatment for various cancers, including colorectal cancer, lung cancer, and ovarian cancer. By targeting VEGF, it helps limit tumor growth by restricting blood supply. However, its use requires close monitoring for potential side effects, particularly concerning blood pressure and bleeding risks. Always consult with your healthcare provider for personalized treatment guidance.

Axishil 5 mg Tablets

Active Ingredient:
Each tablet of Axishil contains 5 mg of Axitinib, an active ingredient classified as a tyrosine kinase inhibitor.

Indication:
Axishil is primarily used for the treatment of renal cell carcinoma (RCC), which is a type of kidney cancer. It is typically prescribed for patients with advanced or metastatic RCC who have previously undergone treatment with other therapies.

Mechanism of Action:
Axitinib, the active ingredient in Axishil, works by inhibiting multiple tyrosine kinases involved in the growth and spread of cancer cells. It specifically targets the vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, which play a crucial role in tumor blood vessel development (angiogenesis). By blocking these receptors, Axishil helps to prevent the formation of blood vessels that supply nutrients to the tumor, effectively slowing down the progression of the cancer.

Dosage and Administration:
The recommended starting dose of Axishil is 5 mg taken orally twice daily. The dosage may be adjusted depending on the patient’s response and tolerability. It is advised to take the tablets at the same time each day, either with or without food. It is important to swallow the tablets whole and not chew or crush them.

Dose Adjustment:
Dose adjustments may be necessary based on side effects, such as high blood pressure, fatigue, or gastrointestinal symptoms. If side effects are intolerable, the dose may be reduced, or therapy may be interrupted. Close monitoring by a healthcare professional is essential during treatment.

Contraindications:

• Hypersensitivity to Axitinib or any of the excipients in Axishil tablets.
• Severe liver impairment.
• Pregnancy and breastfeeding: Axishil is contraindicated during pregnancy due to potential harm to the fetus. It is also not recommended for breastfeeding mothers.

Warnings and Precautions:

• Hypertension: Axishil can cause high blood pressure, which needs to be monitored regularly. If significant hypertension occurs, blood pressure should be managed before continuing the treatment.
• Gastrointestinal perforations and fistulas: Rare but serious side effects, including perforations in the gastrointestinal tract, may occur. Patients should be monitored for symptoms like severe abdominal pain, nausea, and vomiting.
• Thromboembolic events: There is a risk of blood clots with Axishil treatment, including deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Liver toxicity: Liver function should be monitored as liver damage can occur, especially in those with pre-existing liver conditions.
• Wound healing: Since Axishil inhibits angiogenesis, it can interfere with wound healing. It should be discontinued before surgeries and not resumed until after the wound has completely healed.

Side Effects:
Common side effects include:

• High blood pressure (hypertension)
• Fatigue
• Diarrhea
• Nausea and vomiting
• Decreased appetite
• Weight loss

Serious but less common side effects include:

• Gastrointestinal perforations
• Thromboembolic events (blood clots)
• Liver toxicity

Drug Interactions:

• CYP3A4 inhibitors (e.g., ketoconazole) may increase Axishil levels in the blood, requiring dose reduction.
• CYP3A4 inducers (e.g., rifampin) may decrease Axishil efficacy and may require dose adjustments.

Storage:
Store Axishil at room temperature (15-30°C or 59-86°F) in a dry place, away from direct light and moisture. Keep out of reach of children.